US
AWAIT
We at Nordic Science Investments (NSI) partner with founders to transform groundbreaking university research into successful startups.
Committed to both profit and impact, we accelerate the journey from scientific discovery to market, creating meaningful career opportunities and driving technological advancement.
We invest in early-stage, science-based startups and university spinouts in the New Nordics, with a focus on deeptech, health tech, and life sciences.
Pre-seed is our sweet spot, where we help bridge the gap between academia and commercialization, derisking teams for further investment and co-investing with others.
With follow-on capacity of up to €5M per company, we support business development, team building, strategic guidance, and provide access to our global expert network.
Our investments range from €50k–100k at pre-seed, €400-600k at seed, €1-1.5M for Series A, and up to €3.5M for Series B.
Our mission is to turn hidden scientific discoveries into groundbreaking innovations that redefine industries and improve lives. We partner with founders and universities who share our vision of promoting global sustainability and well-being.
By fueling growth in disruptive sectors such as advanced materials, AI-driven technologies, and synthetic biology, we empower innovative solutions that address global challenges. Our commitment goes beyond financial returns—we are dedicated to creating a lasting, positive impact on society by advancing science that truly matters.
We excel in early-stage investing, supporting ventures from day one. Our value extends beyond capital, offering synergistic deals and a partner network managing similar vehicles in the UK and North America—resources that surpass traditional VC networks. This access accelerates growth and boosts outcomes.
We strengthen Tech Transfer Offices’ commercialization efforts by partnering with universities, generating superb deal flow through their IP screening expertise. We also attract top spinout CEOs who value our specialist approach, helping mitigate early-phase investment risks.
